Skip to content
Screener

Insight Molecular Diagnostics Inc. IMDX Q4 2025 Annual earnings

Reported March 26, 2026 · After market close

Revenue$1.1MBeat by $854.0K
EPS-$0.27Miss by $0.03
Revenue estimate$285.0K
EPS estimate-$0.24

Next report

Nov 9, 2026 (in 2 months)
Revenue estimate$215.1K
EPS estimate-$0.23

Financials

Q4 2025

Income statement

See full
Revenue$1.1M-23.4%
Gross profit$496.0K-19.6%
Operating income-$23.4M+30.3%
Net income-$23.0M+31.5%
EPS (diluted)-$0.74+67.8%

Balance sheet

See full
Cash & equivalents$11.6M+34.1%
Total debt$3.3M-6.8%
Total equity-$31.5M-156%
Total assets$25.8M-26.6%

Cash flow

See full
Operating cash flow-$5.5M-3.6%
CapEx$1.5M+591%
Free cash flow-$7.0M-26.2%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$214.98M—
Enterprise value$206.72M—
P/S53×—

Profitability

See full
Gross margin56.7%+12.7pp
Operating margin-1,260.8%-478pp
Net margin-1,238.5%-472pp
FCF margin-625.6%-193pp

Returns & leverage

See full
Current ratio1.3×-0.3×

Segments

By geography

See full
Asia Pacific-—

FAQ

When did Insight Molecular Diagnostics Inc. report Q4 2025 earnings?
Insight Molecular Diagnostics Inc. (IMDX) reported Q4 2025 earnings on March 26, 2026 after market close.
What were Insight Molecular Diagnostics Inc.'s Q4 2025 revenue and EPS?
Insight Molecular Diagnostics Inc. reported revenue of $1.1M and eps of $-0.27 for Q4 2025.
Did Insight Molecular Diagnostics Inc. beat estimates in Q4 2025?
Revenue beat the consensus estimate of $285.0K by $854.0K. EPS missed the consensus estimate of $-0.24 by $0.03.
How did Insight Molecular Diagnostics Inc.'s Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 23.4% from $1.5M a year earlier.
Where can I find Insight Molecular Diagnostics Inc.'s Q4 2025 SEC filings?
You can read the 8-K earnings release (0001493152-26-012915) and the 10-K periodic report (0001642380-26-000004) directly on SEC EDGAR. The filing index links above go to sec.gov.